Clinical trials are critical for developing new treatments, but the industry faces chronic delays. About 70% of trials encounter startup delays, and almost six in 10 trials experience costly amendments. These amendments average between $250-450K in direct costs alone, and slows down patient access to potentially lifesaving treatments. Many of these issues arise from poorly designed protocols, miscommunications at trial sites, and logistical errors, and a typical large pharma could save tens of millions annually by leveraging effective AI solutions.

Founded by a team with deep roots in life sciences, Biorce directly addresses these operational inefficiencies holding back clinical progress. The company’s technology simplifies the process from start to finish – everything from patient recruitment to designing trial protocols and choosing the right trial sites. The aim is to cut down on delays, boost success rates, and speed up access to critical treatments.

At the core is the AI native platform, Jarvis, that helps teams make better decisions early in the process. It offers tailored recommendations and predicts which sites are most likely to succeed, helping trial sponsors avoid common pitfalls. That means less time lost, fewer costly mistakes, and a faster, more efficient path to bringing new therapies to market.

Biorce’s AI platform is already making a measurable impact in clinical trial planning and protocol design, with adoption by leading pharmaceutical companies, biotechs, and CROs. Designed to be a fully therapeutic area–agnostic, the platform is currently powering programmes across oncology, neurology, and beyond, accelerating time-to-market by enabling smarter, faster decisions. As examples, in oncology, it helped rapidly iterate a Phase II solid tumour protocol, refining inclusion criteria in line with evolving regulatory guidance. In neurology, it supported protocol development and site strategy for a multicentre Alzheimer’s trial by integrating prior trial data and real-world benchmarks at the earliest stages.

Pedro Coelho, CEO, Biorce, commented: “We’re tackling the root causes of delay and inefficiency in clinical trials: issues that cost time, money, and ultimately lives. Our solution cuts through complexity, shortens timelines, and improves outcomes for patients. When my father was diagnosed with cancer, we were lucky to find a clinical trial that extended his life by ten months, but that kind of access is far from the norm. Our goal is to make clinical trials faster and cheaper so that we can get those opportunities to all patients and not just those lucky enough to join a trial.”

The clinical trial market, projected to grow from $84 billion in 2024 to $150 billion by 2034, sees increasing pharma R&D expenditure. AI-driven solutions like Biorce’s Jarvis are poised to unlock $13-25 billion in industry value, significantly reducing trial amendments by 30-50% and speeding protocol improvements by 25%.

Having been part of Norrsken Barcelona from its early beginnings, Biorce has experienced significant client interest and doubled its team size since its first round in November 2024. The company is currently operating in Spain, the UK and the Nordics, and the funding will be used to expand the sales team in the US, accelerate product development and enable the company to grow from seven to eight digit revenue.

Recently, Norrsken VC – together with Norrsken Launcher and Norrsken Accelerator – announced a €300 million commitment to back European startups using AI to tackle the world’s most pressing challenges.

Tove Larsson, General Partner at Norrsken VC, commented: “Biorce is exactly the kind of pioneering company we’re here to back. They’re combining deep sector expertise with cutting-edge AI to solve what truly matters. Their platform has the potential to radically reduce both the time and cost of bringing new treatments to market, unlocking huge value for pharma and, more importantly, faster access to life-saving therapies for patients.”

Markus Feuerecker, Founding Partner at YZR Capital, said: "We’re proud to have backed Biorce early in 2024. From day one, we had strong conviction in the team and the market. The early traction has been outstanding, and it’s been exciting to watch their momentum build. We’re thrilled to welcome Norrsken VC on board and to join forces in supporting Biorce on its mission to transform clinical trials.”

Sofia Queiroz, Investment Principal at Mustard Seed Maze: “Biorce’s journey since we backed Pedro and the team has been truly impressive – from strong product development and real-world outcomes to tangible commercial traction. This rapid growth demonstrates that the company is addressing a genuine market need and has the right team in place to capture the opportunity. We’re excited to continue supporting Biorce and to welcome Norrsken VC as a fellow impact investor on this journey.”

For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.